Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial

The vaccine demonstrated 100% efficacy in a Phase III trial in adolescents aged 12 to 15 years old

15 million Johnson & Johnson coronavirus vaccines ruined due to human error: NYT esagonowsky Wed, 03/31/2021 – 17:53